Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from SynAct Pharma AB ( (SE:SYNACT) ) is now available.
SynAct Pharma AB held its annual general meeting in Stockholm, where key resolutions were adopted, including the approval of financial statements and the decision to carry forward available funds without issuing dividends. The meeting also saw the re-election of board members and the authorization for the board to issue new shares, allowing for potential capital raising and strategic partnerships, which could impact the company’s growth and market positioning.
More about SynAct Pharma AB
SynAct Pharma AB operates in the pharmaceutical industry, focusing on developing innovative therapies for inflammatory diseases. The company is committed to advancing treatments that address unmet medical needs, leveraging its expertise in drug development and strategic partnerships.
Average Trading Volume: 187,789
Current Market Cap: SEK888M
For detailed information about SYNACT stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue